Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASAOSL:VISTN -4.46%80 OCF Margin % is 33.22% as of Jun. 2026, which is 384% above its 10-year median of 6.86. GuruFocus rates OSL:VISTN with a GF Score™ of 80/100 and a GF Value™ of kr23.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 960 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 82.81% on this metric.
The historical data trend for Vistin Pharma ASA's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:VISTN vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (OSL:VISTN) has a OCF Margin % of 33.22% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vistin Pharma ASA and its competitors. This is 384% above median its historical median of 6.86. According to the industry distribution chart, Vistin Pharma ASA ranks #165 out of 960 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is Vistin Pharma ASA's OCF Margin % too high?
Vistin Pharma ASA's current OCF Margin % of 33.22% is 384% above median its 10-year median of 6.86. The Drug Manufacturers industry median OCF Margin % is 9.75. Vistin Pharma ASA's value of 33.22% is 240.7% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #165 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #165 out of 960 companies for OCF Margin %. This places Vistin Pharma ASA in the top 17% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.75. Vistin Pharma ASA's value of 33.22% is 240.7% above this benchmark. While the company's 10-year median is 6.86 vs. the industry median of 9.75, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.75, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current OCF Margin % of 33.22% is 240.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current OCF Margin % is 33.22%, which is 384% above median its own 10-year median of 6.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.39, compared to a current price of kr19.30 — trading 17.5% below its estimated fair value. The current OCF Margin % is 33.22%, which is 384% above median its 10-year median of 6.86 and 240.7% above the Drug Manufacturers industry median of 9.75. Vistin Pharma ASA's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current OCF Margin % is 33.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr19.30 is trading 17.5% below its estimated GF Value™ of kr23.39.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for OSL:VISTN:
OCF Margin %: 33.22% (384% above median its 10-year median of 6.86)
GF Value™: kr23.39 vs. price of kr19.30 (17.5% below fair value)
Industry Position: 240.7% above the Drug Manufacturers median (#165 of 960)
No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score
Get the complete analysis for OSL:VISTN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:VISTN has been successfully added to your 
